Clinical Trial

A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer

Name: A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer — clinical trial record (NCT07649928)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

ESSIGHT-HJG-ES502-01 is a dose-escalation study of ES502 in patients with advanced pancreatic cancer. The study will enroll patients with advanced, RAS G12V positive pancreatic cancer who have no effective treatment options available (HLA genotyping required).

Trial Details

NCT Number	NCT07649928
Lead Sponsor	Ruijin Hospital Collaborators: Shanghai Essight Bio Co.,Ltd
Conditions	Pancreatic Cancer
Enrollment	24 participants
Start Date	2026-05-18
Primary Completion	2028-12 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-16